More than six years after SARS-CoV-2 reshaped life across the globe, the acute phase of the pandemic has ended, but for tens of millions of people, the illness has not. A significant proportion of those infected with the virus developed persistent, debilitating symptoms that have not resolved with time, now known as Long COVID. For those of us who have spent years treating patients with Chronic Fatigue Syndrome (ME/CFS) and Chronic Lyme Disease, the clinical presentation is very familiar – profound fatigue, cognitive impairment, post-exertional malaise, and a medical system that was slow to believe any of it.
The emergence of Long COVID has brought awareness to the biological reality that post-infectious chronic illness does exist. The mechanisms in Long COVID — mitochondrial dysfunction, immune dysregulation, pathogen persistence, autonomic dysfunction, and autoimmunity — are the same mechanisms long proposed in Chronic Fatigue Syndrome (ME/CFS) and Chronic Lyme Disease. The science is converging toward a unifying framework for post-infectious chronic illness, with deep clinical implications for all three conditions.
Three Conditions, One Clinical Pattern
Long COVID, ME/CFS, and Chronic Lyme Disease present to clinicians with strikingly similar profiles despite arising from different infectious triggers. Long COVID is defined by symptoms persisting 12 weeks or more after SARS-CoV-2 infection, not explained by an alternative diagnosis, and can follow even mild acute illness. ME/CFS is a severe, chronic, multisystem disease characterized by profound fatigue unimproved by rest, post-exertional malaise (PEM), unrefreshing sleep, cognitive impairment, and orthostatic intolerance, most commonly triggered by a preceding infection. Chronic Lyme disease encompasses the persistent illness that follows Borrelia burgdorferi infection, including cases that continue long after antibiotic treatment, and shares with the other two conditions a clinical picture of fatigue, cognitive impairment, musculoskeletal pain, sleep disturbance, and autonomic dysfunction.
All three conditions share a history of being dismissed, under-researched, and misattributed to anxiety or functional illness. All three are now understood to have measurable, reproducible biological signatures. And all three represent variations on a common disease process, one that converts an acute infectious insult into a chronic state of cellular and immune dysfunction.
A Shared Symptom Profile
The symptom overlap across Long COVID, ME/CFS, and Chronic Lyme Disease is impressive and well-documented. A 2023 review found that in most chronic Lyme disease studies, at least four of the six major ME/CFS diagnostic criteria were also present.1 Another study found that 58% of Long COVID patients met full ME/CFS case criteria, with post-exertional malaise reported in 82.8% of the cohort.2 A large patient outcomes survey found that 89.7% of ME/CFS patients and 79.4% of Long COVID patients reported PEM, strongly suggesting a shared underlying mechanism.3
The following symptoms appear consistently across all three conditions:
- Disabling fatigue — not relieved by rest
- Post-exertional malaise (PEM) — symptom worsening after physical or cognitive exertion, often delayed 12–48 hours and lasting days to weeks
- Cognitive dysfunction (“brain fog”) — impaired memory, processing speed, and word-finding
- Unrefreshing sleep — waking without restoration regardless of hours slept
- Orthostatic intolerance and dysautonomia — lightheadedness, syncope, or POTS
- Musculoskeletal pain — muscle and joint pain without elevated inflammatory markers
- Headaches — pressure, tension, or migraine-type
- Immune-type symptoms — recurrent sore throat, tender lymph nodes, flu-like episodes
- Neurosensory disturbances — sensitivity to light, sound, and chemical triggers
- Cardiovascular symptoms — palpitations, chest tightness, reduced exercise tolerance
- Anxiety and mood disturbances — frequently secondary to neurological involvement
Converging Mechanisms
What began as parallel observations in three separate disease communities has converged into a coherent picture of shared biological dysfunction. Four mechanisms appear to be most consistently implicated: mitochondrial dysfunction, immune dysregulation (including mast cell activation), autoimmunity, and pathogen or antigen persistence. In patients, these mechanisms do not operate in isolation. They interact and compound one another.
Mitochondrial Dysfunction and Cellular Energy Failure
Mitochondria produce 90–95% of the body’s ATP and are adversely affected in all three conditions. When mitochondrial function is impaired, energy production falls, immune function deteriorates, and the function of organs with the highest metabolic demands, such as the heart, brain, and skeletal muscle, begins to decline. This is specifically the organ distribution that characterizes these illnesses.
In ME/CFS, studies have directly confirmed mitochondrial damage in skeletal muscle. A 2025 study found elevated brain lactate in ME/CFS patients, a direct marker of anaerobic metabolism and energetic stress.4 Proteomic analysis following exercise found persistent upregulation of glycolysis pathways consistent with mitochondrial impairment, explaining why even modest exertion produces disproportionate and prolonged symptom flares.
In Long COVID, SARS-CoV-2 has been shown to directly disrupt mitochondrial function by increasing reactive oxygen species, impairing mitophagy, and altering membrane integrity.5 A 2024 study found that skeletal muscle abnormalities worsen after PEM is induced, with metabolic disturbances consistent with mitochondrial failure underlying the crash.6
In chronic Lyme disease, a genome-wide association study identified a suggestive susceptibility near the MARC2 gene, which is linked to multiple immune checkpoints. This genetic association suggests heritable differences in mitochondrial function may partly determine who develops persistent Lyme symptoms after antibiotic treatment.7 Metabolomic studies have also identified dysregulation of lipid metabolism in chronic Lyme disease, consistent with impaired mitochondrial fatty acid oxidation.
Immune Dysregulation
The immune system in these conditions is both overactivated and functionally exhausted. Chronic activation depletes the resources needed for an effective immune response, creating a self-perpetuating cycle. Multiple layers of immune dysfunction have been documented across all three conditions.
T cell and complement dysregulation are well-characterized in Long COVID. Studies have documented persistent systemic inflammation lasting for 8 or more months after infection, exhausted SARS-CoV-2-specific CD8+ T cells, and elevated CD4+ T cells primed to migrate to inflamed tissues.8 9 In ME/CFS, single-cell RNA sequencing has characterized classical monocyte dysregulation that correlates with disease severity, and a 2025 study found no statistically significant differences in core immune biomarkers between people with ME/CFS and Long COVID.10 In chronic Lyme disease, a 2025 study documented aberrant T cell phenotypes distinguishing Chronic Lyme patients from healthy controls.11
Mast Cell Activation Syndrome
Mast cell activation syndrome (MCAS) has emerged as a significant and underrecognized component of immune dysregulation across all three conditions. Mast cells are innate immune cells that release a cascade of mediators when activated. The mediators, including histamine, prostaglandins, leukotrienes, and cytokines, drive neuroinflammation, vascular instability, and systemic symptoms. One study found that Long COVID patients and MCAS patients showed virtually identical mast cell activation symptom profiles, with nearly identical symptom severity scores.12 Research has proposed that SARS-CoV-2 spike protein directly activates mast cells and microglia (immune cells in the central nervous system), causing neuroinflammation in Long COVID.13
In ME/CFS, a 2025 study found that up to 25.3% of ME/CFS patients met criteria for clinically relevant mast cell activation, with MCAS-positive patients showing significantly higher rates of dysautonomia and POTS, and better clinical responses to mast cell-targeted treatment.14 In Chronic Lyme Disease, MCAS can exacerbate immune dysregulation, and is recognized as a comorbidity requiring separate management.
Dysautonomia, including POTS, is a clinically important manifestation of this immune dysregulation. Dysautonomia is well-documented in Long COVID, and a 2024 review article proposed that it is also a key, underrecognized feature of chronic Lyme Disease, sharing mechanisms with both Long COVID and ME/CFS.15
Autoimmunity and Molecular Mimicry
Molecular mimicry is a mechanism in which antibodies formed against a pathogen also react with similar human proteins. It is a well-established mechanism by which infections trigger self-perpetuating autoimmune disease.
In Long COVID, research found that SARS-CoV-2 antibodies cross-reacted with 28 of 55 human tissues tested, including mitochondria, thyroid, muscle, and brain.16 A 2024 study confirmed newly formed autoantibodies persisted at least 12 months post-infection, with sequence similarities to the SARS-CoV-2 spike protein.17 Another study found that 83% of post-COVID syndrome patients showed latent autoimmunity.18 Thyroid autoimmunity deserves specific attention. A 2024 study found a significant association between elevated anti-thyroid peroxidase (anti-TPO) antibodies and Long COVID symptoms persisting to 23 months after infection. 19
In ME/CFS, autoantibodies targeting adrenergic receptors and muscarinic acetylcholine receptors have been identified as contributors to autonomic dysfunction. Reactivation of latent herpesviruses, particularly Epstein-Barr virus (EBV) and HHV-6, is well-documented in ME/CFS and has been found in Long COVID, where elevated EBV antibody titers were among the top immune biomarkers distinguishing Long COVID in a landmark study.20
In chronic Lyme disease, Borrelia burgdorferi triggers autoimmune responses through molecular mimicry, primarily in Lyme arthritis. Broader autoimmune reactivity, including neurological involvement, contributes to the cognitive and systemic symptoms of chronic Lyme disease. A full autoimmune panel should be part of the evaluation for all three conditions.
Pathogen and Antigen Persistence
Persistent illness after acute infection may result from ongoing pathogen presence, residual antigen stimulation from pathogen fragments, or immune memory that continues to drive activation in the absence of active infection. Evidence for one or more of these mechanisms now exists across all three conditions.
In Long COVID, a 2024 study used whole-body PET imaging to demonstrate elevated T-cell activation in multiple tissues (brainstem, spinal cord, bone marrow, and cardiopulmonary tissues) up to 2.5 years after initial infection. In a subset of patients, SARS-CoV-2 RNA was detected in tissue samples up to 676 days post-infection, and this was directly associated with ongoing systemic immune activation.21
In chronic Lyme disease, borrelial RNA and DNA are frequently detected in animal studies following antibiotic treatment, and human studies have identified persistent inflammatory gene expression patterns distinct from those observed during acute infection. Whether driven by live organisms, residual antigens, or immune memory, the clinical result is a patient with chronic immune activation and debilitating symptoms long after the original infection.22
In ME/CFS, the triggering pathogen is often not conclusively identified, but post-infectious onset is well established. The SARS-CoV-2 experience has provided the clearest window into how an acute infection can establish a persistent biological state, illuminating ME/CFS in the process.
Co-infections and the Role of Pre-existing Conditions
An underappreciated clinical reality is that these conditions do not exist in a microbiological vacuum. Bartonella, Mycoplasma, and Borrelia infections have all been reported to reactivate during acute COVID. Patients who develop persistent symptoms after SARS-CoV-2 infection may have had underlying low-grade infections that were unmasked or amplified by the acute illness. Conversely, chronic Lyme disease patients may have their condition worsened by a subsequent COVID infection or may develop Long COVID on top of an already-compromised immune state.
Lessons the Medical Community Must Not Repeat
In 2021, Johns Hopkins physician John Aucott, MD, cautioned against making the same mistakes with Long COVID that were made with Lyme disease and ME/CFS. He noted that chronic Lyme disease had remained “fiercely contentious for more than 30 years.”23 That warning has proven partially correct – Long COVID patients gained recognition faster than chronic Lyme disease, but continue to face inadequate testing, symptom-only treatment, and dismissal when they do not recover on expected timelines.24
The shared biology outlined in this article is not random. These conditions share mechanisms because they involve a common disease process: the transition of an acute infection into a chronic state of cellular energy failure, immune dysregulation, and nervous system dysfunction. Physicians with experience in ME/CFS and Chronic Lyme Disease bring direct clinical knowledge to Long COVID, and the research on Long COVID has provided the ME/CFS and Chronic Lyme Disease communities with a detailed biological characterization of their conditions.
Its All Connected
Long COVID, ME/CFS, and Chronic Lyme Disease share similar mechanisms, and that shared pathophysiology is now documented in peer-reviewed literature with a level of detail that was unavailable a few years ago. Mitochondrial failure, immune dysregulation, mast cell activation, autoimmunity, autonomic dysfunction, and pathogen or antigen persistence are the common threads. The specific triggering pathogen matters for initial treatment, but the collateral damage that follows infectious exposure also necessitates effective treatment.
The clinical objective is clear – apply the same attention we bring to any complex multisystem disease, act on the mechanistic evidence now available, and listen to patients who have known for years what the research is only now confirming.
